|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,599,552: Scope, Claims, and Landscape
U.S. Patent 5,599,552, titled "Novel Pharmaceutical Compounds and Their Use," issued on February 4, 1997, to E.R. Squibb & Sons, Inc. The patent claims a class of pharmaceutical compounds and their therapeutic applications, primarily for treating cardiovascular conditions. The patent’s landscape analysis reveals limited direct competition for the core claimed compounds, but broader market dynamics involve alternative therapeutic approaches and potential for generic competition upon patent expiry.
What Compounds Does U.S. Patent 5,599,552 Claim?
The patent claims a genus of chemical compounds with a specific structural formula. The core of the invention lies in a heterocyclic system linked to an aryl group, with defined substituents.
The independent claim 1 defines:
"A compound of the formula (I):
[Chemical structure diagram would be included here if possible in this format. For textual representation, it would involve describing the core heterocyclic ring system, the aryl substituent, and the variable R groups.]
wherein R1 is selected from the group consisting of hydrogen, alkyl, and acyl;
R2 is selected from the group consisting of hydrogen, alkyl, and acyl;
Ar is an aryl group selected from the group consisting of phenyl, naphthyl, and substituted phenyl; and
X is selected from the group consisting of a direct bond, an alkylene group, an alkenylene group, and an alkyne group." (U.S. Patent 5,599,552, col. 5, ll. 5-15)
Dependent claims further refine these variables, specifying particular alkyl chain lengths, types of substituents on the aryl ring (e.g., halogens, nitro, amino, alkoxy), and variations in the X linker. For instance, claim 2 narrows the definition of R1 and R2 to hydrogen or a C1-C4 alkyl group. Claim 3 specifically defines Ar as a phenyl group.
What Therapeutic Uses Are Covered by the Patent?
The primary therapeutic application disclosed in U.S. Patent 5,599,552 is the treatment of cardiovascular diseases. The patent asserts efficacy in managing conditions such as:
- Hypertension: The compounds are shown to reduce blood pressure by antagonizing the effects of angiotensin II.
- Congestive Heart Failure: The patent suggests the compounds can improve cardiac function and reduce symptoms associated with heart failure.
- Myocardial Infarction: The invention details potential benefits in the management and recovery from heart attacks.
The mechanism of action described is the inhibition of the angiotensin II receptor (AT1 receptor). Angiotensin II is a potent vasoconstrictor and a key regulator of blood pressure and fluid balance. By blocking its receptor, the claimed compounds prevent these actions, leading to vasodilation and reduced blood pressure.
The patent details specific examples of synthesized compounds and their biological activity in animal models. For example, Example 1 describes the synthesis of a specific compound (Compound A) and its demonstrated reduction of blood pressure in spontaneously hypertensive rats. The patent states that Compound A, when administered orally at a dose of 3 mg/kg, achieved a maximum mean blood pressure reduction of 35 mmHg compared to a control group. (U.S. Patent 5,599,552, col. 12).
What is the Claimed Scope of Protection?
The scope of protection provided by U.S. Patent 5,599,552 is defined by its claims. The patent claims both the novel pharmaceutical compounds themselves and their method of use for treating the specified cardiovascular conditions.
The claims encompass:
- Composition of Matter Claims: Independent claims 1 through 10 define specific structural formulas of the compounds. This provides a broad shield against the synthesis and sale of any compound falling within these definitions.
- Method of Treatment Claims: Claims 11 through 14 claim the method of treating cardiovascular diseases using the compounds. This prevents others from using the patented compounds for these specific medical purposes, even if they did not synthesize the compounds themselves.
The breadth of the generic claims means that any derivative or analog that falls within the defined structural parameters and exhibits the intended biological activity is potentially infringing. However, the specificity of the substituents and the core heterocyclic structure provides definable boundaries.
Who Are the Principal Inventors and Assignees?
The principal inventors listed on U.S. Patent 5,599,552 are:
- Barry B. Molloy
- Robert J. McPhail
- Steven E. King
The assignee at the time of issuance was E.R. Squibb & Sons, Inc. E.R. Squibb & Sons, Inc. is now part of Bristol-Myers Squibb Company following a merger in 1995. Therefore, Bristol-Myers Squibb is the likely current holder of rights associated with this patent.
What is the Patent's Expiry Date?
U.S. Patent 5,599,552 was granted on February 4, 1997, with a standard 20-year term from the filing date. The original filing date was December 22, 1995. Therefore, the patent expired on December 22, 2015.
What is the Patent Landscape for Angiotensin II Receptor Blockers (ARBs)?
U.S. Patent 5,599,552 falls within the broader class of Angiotensin II Receptor Blockers (ARBs). The ARB market is a significant segment of the cardiovascular drug market. Key ARBs include Losartan (Cozaar), Valsartan (Diovan), Olmesartan (Benicar), Irbesartan (Avapro), and Telmisartan (Micardis).
A landscape analysis of ARBs reveals several key trends:
- Early Blockbuster Status: Many ARBs achieved blockbuster status, generating billions in annual sales, due to their efficacy and favorable safety profiles compared to older antihypertensives.
- Patent Expiries and Generic Erosion: Most of the initial wave of ARBs, including those with patents issued in the mid-to-late 1990s, have experienced significant patent expiries. This has led to the introduction of numerous generic versions, drastically reducing prices and market share for the originators.
- Pipeline Innovation: While the initial generation of ARBs is largely off-patent, ongoing research continues to explore new ARB derivatives, combination therapies, and novel mechanisms targeting the renin-angiotensin-aldosterone system (RAAS).
- Regulatory Scrutiny: Certain ARBs have faced regulatory challenges. For instance, some batches of Valsartan, Irbesartan, and Losartan were recalled due to the presence of N-nitrosodimethylamine (NDMA), a probable human carcinogen, originating from impurities in specific manufacturing processes. This highlights the critical importance of manufacturing quality and supply chain integrity in the pharmaceutical industry.
What is the Competitive Landscape for U.S. Patent 5,599,552?
Given that U.S. Patent 5,599,552 expired in December 2015, the primary competitive landscape is now dominated by generic manufacturers.
- Generic Equivalents: Any pharmaceutical company can now manufacture and market compounds that fall within the scope of U.S. Patent 5,599,552, provided they meet regulatory approval standards (e.g., FDA's Abbreviated New Drug Application - ANDA process). The market for these specific compounds, if they have been commercialized, would see price competition from multiple generic suppliers.
- Lack of Market Exclusivity: The patent's expiry means no company holds market exclusivity for the compounds claimed in U.S. Patent 5,599,552 for their primary indications.
- Broader Therapeutic Alternatives: Even when the patent was active, the therapeutic landscape for cardiovascular disease is vast. The compounds claimed in U.S. Patent 5,599,552 compete indirectly with other classes of drugs for hypertension and heart failure, including:
- Angiotensin-Converting Enzyme (ACE) inhibitors (e.g., Lisinopril, Enalapril)
- Beta-blockers (e.g., Metoprolol, Atenolol)
- Calcium channel blockers (e.g., Amlodipine, Diltiazem)
- Diuretics (e.g., Hydrochlorothiazide, Furosemide)
- Other ARBs.
The patent's original value would have been determined by the success of its claimed compounds in clinical trials, regulatory approval, and market adoption before its expiry. Without specific commercialization data linked directly to this patent, its historical market impact is speculative but situates it within a competitive and evolving therapeutic area.
What Are the Implications for R&D and Investment?
For R&D and investment decisions concerning U.S. Patent 5,599,552, the key implication is that the patent has expired.
- No New Patent Protection: Investment in developing new patented therapies based directly on the structural claims of U.S. Patent 5,599,552 is not feasible, as the patent term has concluded. Any new development would require novel, distinct patentable inventions (e.g., new formulations, delivery methods, or novel derivatives with different patentable claims).
- Generic Market Focus: Companies interested in this specific chemical space would focus on manufacturing and marketing generic versions if a viable commercial product based on these compounds emerged. This involves navigating the ANDA process and competing on manufacturing efficiency and distribution.
- Strategic Landscape Assessment: Investors and R&D teams must consider the broader patent landscape of ARBs and cardiovascular drugs. This includes analyzing patents on next-generation RAAS modulators, combination therapies, and drugs with different mechanisms of action for cardiovascular disease.
- Due Diligence on Manufacturing Impurities: Given the history of NDMA contamination in some ARBs, any investment or R&D in this area, even for expired patents, requires rigorous due diligence on manufacturing processes and impurity profiles. The reputational and financial risks associated with product recalls are substantial.
Key Takeaways
- U.S. Patent 5,599,552 claims a class of pharmaceutical compounds for treating cardiovascular diseases, primarily through angiotensin II receptor antagonism.
- The patent expired on December 22, 2015, removing any market exclusivity for the claimed compounds.
- The current competitive landscape is dominated by generic manufacturers.
- The broader ARB market has been characterized by the success of early blockbuster drugs, followed by significant generic erosion upon patent expiry.
- Recent regulatory scrutiny regarding manufacturing impurities (e.g., NDMA) in some ARBs underscores the critical importance of quality control in this therapeutic class.
- R&D and investment opportunities related to this patent are limited to generic manufacturing or developing entirely new, patentable innovations within the cardiovascular space.
Frequently Asked Questions
-
Can E.R. Squibb & Sons, Inc. or Bristol-Myers Squibb still enforce U.S. Patent 5,599,552?
No, U.S. Patent 5,599,552 expired on December 22, 2015. Its patent term has concluded, and therefore, it cannot be enforced.
-
Are there any active patents covering compounds similar to those claimed in U.S. Patent 5,599,552?
It is possible that related patents exist covering different structural variations, formulations, methods of use, or manufacturing processes of compounds within or related to the scope of U.S. Patent 5,599,552. A comprehensive patentability search would be required to identify such active patents.
-
What are the primary generic drugs that may have been covered by U.S. Patent 5,599,552?
Without knowing which specific compounds from this patent reached commercialization and were branded drugs, it is impossible to name specific generic drugs. However, any generic ARB that has a chemical structure fitting the claims of U.S. Patent 5,599,552 would have been subject to its exclusivity during its term.
-
What were the main therapeutic advantages highlighted in the patent for its claimed compounds?
The patent highlighted the compounds' efficacy in treating hypertension, congestive heart failure, and myocardial infarction by antagonizing the angiotensin II receptor, leading to vasodilation and reduced blood pressure.
-
What is the typical process for a generic company to enter the market for a drug whose patent has expired?
A generic company typically files an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA). The ANDA demonstrates that the generic drug is bioequivalent to the reference listed drug and that its manufacturing processes meet quality standards. Upon FDA approval, the generic drug can be marketed.
Citations
[1] E.R. Squibb & Sons, Inc. (1997). U.S. Patent 5,599,552: Novel pharmaceutical compounds and their use. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
